RTP Mobile Logo
Exploring Current Management Paradigms for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Therapy
Released March 2020

Proceedings from a roundtable discussion with Drs Courtney D DiNardo, Keith W Pratz, Richard M Stone and a group of 20 general medical oncologists and nurse practitioners on the optimal management of acute myeloid leukemia within a community-based setting. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

    AML is the most common form of leukemia among adults, and in 2019 an estimated 21,450 cases were diagnosed and 10,920 individuals died from this disease. This disease commonly affects older patients (≥65 years), who often respond poorly to induction chemotherapy or who may not be candidates for conventional cytotoxic induction therapies. Patients who are medically unfit for standard induction therapy have limited treatment options. In the past few years novel agents and approaches, including inhibitors of Bcl-2, FLT3 and IDH, have changed the management landscape for these patients with AML. However, with these many exciting advances, vexing questions and clinical challenges are emerging. To bridge the gap between research and patient care, this program features discussions with leading hematology-oncology investigators on the current therapeutic paradigm for AML in patients who are not eligible for intensive therapy. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.


    • Consider age, performance status and cytogenetic and molecular alterations in the selection and sequencing of therapy for patients with AML.
    • Recognize the recent FDA approvals of novel agents targeting Bcl-2 and the hedgehog signaling pathway for patients with newly diagnosed AML who are 75 years or older and ineligible for intensive therapy, and discern how these therapies can be optimally integrated into clinical practice.
    • Evaluate published research data and clinical investigator perspectives regarding the management of AML with an actionable genomic alteration (eg, FLT3, IDH1/2), and use this information to develop optimal treatment plans for patients.
    • Develop a plan of care to recognize and manage side effects associated with the use of existing and recently approved systemic therapies for AML.
    • Identify the mechanisms of action of investigational agents and recall new data demonstrating promising activity in AML.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Courtney D DiNardo, MD, MSCE
    Associate Professor, Department of Leukemia
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Jazz Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Notable Labs.

    Keith W Pratz, MD
    Associate Professor of Medicine
    Director of Leukemia Program
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Boston Biomedical Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Takeda Oncology.

    Richard M Stone, MD
    Director, Translational Research, Leukemia Division
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Amgen Inc, argenx, Arog Pharmaceuticals Inc, Astellas, BioLineRx, Celgene Corporation, Daiichi Sankyo Inc, Novartis, Pfizer Inc, Takeda Oncology, Trovagene; Data and Safety Monitoring Board: argenx, Celgene Corporation, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Genentech, a member of the Roche Group.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2020
    Expiration date: March 2021

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Initial Workup and Determination of Eligibility for Intensive Treatment; Integrating Venetoclax into the Treatment of Acute Myeloid Leukemia (AML)

Management of AML with FLT3 and IDH Mutations

Select Publications